Ben Fidler· @BentheFidler · X·· 2026-04-20Score60
Reading
KRAS / RAS targeting: from platform to Phase 3
zoldonrasib and VS-7375 in G12D remain Phase 1 — strong numbers, small samples, not head-to-head.
Body
AACR 2026: Revolution’s next prospect, Merck’s reveal and a lung cancer battle
https://
biopharmadive.com/news/aacr-2026
-revolution-zoldonrasib-merck-vegf-nuvalent-nuvation/817916/
… #AACR26 $RVMD $MRK $NUVL $NUVB
Heat 0 · 0 likes · 0 replies · 0 reposts
Source: Ben Fidler · x.com